Search

Your search keyword '"Aleman, Berthe M P"' showing total 362 results
Start Over Author "Aleman, Berthe M P"
362 results on '"Aleman, Berthe M P"'

2. Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials

Author

Juul, Sidsel J., Rossetti, Sára, Aleman, Berthe M. P., van Leeuwen, Flora E., van der Kaaij, Marleen A. E., Giusti, Francesco, Meijnders, Paul, Raemaekers, John M. M., Kluin-Nelemans, Hanneke C., Spina, Michele, Krzisch, Daphne, Bigenwald, Camille, Stamatoullas, Aspasia, André, Marc, Plattel, Wouter J., Hutchings, Martin, and Maraldo, Maja V.

Published
2024
Full Text
View/download PDF

3. Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials

Author

Juul, Sidsel J., Rossetti, Sára, Kicinski, Michal, van der Kaaij, Marleen A. E., Giusti, Francesco, Meijnders, Paul, Aleman, Berthe M. P., Raemaekers, John M. M., Kluin-Nelemans, Hanneke C., Spina, Michele, Fermé, Christophe, Renaud, Loïc, Casasnovas, Olivier, Stamatoullas, Aspasia, André, Marc, Le Bras, Fabien, Plattel, Wouter J., Henry-Amar, Michel, Hutchings, Martin, and Maraldo, Maja V.

Published
2024
Full Text
View/download PDF

11. How to Elicit Many Probabilities

Author

van der Gaag, Linda C., Renooij, Silja, Witteman, Cilia L. M., Aleman, Berthe M. P., and Taal, Babs G.

Subjects
Computer Science - Artificial Intelligence
Abstract

In building Bayesian belief networks, the elicitation of all probabilities required can be a major obstacle. We learned the extent of this often-cited observation in the construction of the probabilistic part of a complex influence diagram in the field of cancer treatment. Based upon our negative experiences with existing methods, we designed a new method for probability elicitation from domain experts. The method combines various ideas, among which are the ideas of transcribing probabilities and of using a scale with both numerical and verbal anchors for marking assessments. In the construction of the probabilistic part of our influence diagram, the method proved to allow for the elicitation of many probabilities in little time., Comment: Appears in Proceedings of the Fifteenth Conference on Uncertainty in Artificial Intelligence (UAI1999)

Published
2013

13. Risk of male breast cancer after Hodgkin lymphoma

Author

de Vries, Simone, primary, Krul, Inge M., additional, Schaapveld, Michael, additional, Janus, Cecile P. M., additional, Rademakers, Saskia E., additional, Roesink, Judith M., additional, Nijziel, Marten R., additional, Bilgin, Yavuz M., additional, Aleman, Berthe M. P., additional, and van Leeuwen, Flora E., additional

Published
2023
Full Text
View/download PDF

15. Risk of diabetes after para-aortic radiation for testicular cancer

Author

Groot, Harmke J., Gietema, Jourik A., Aleman, Berthe M. P., Incrocci, Luca, de Wit, Ronald, Witjes, J. Alfred, Groenewegen, Gerard, de Brouwer, Peter, Meijer, Otto W. M., Hulshof, Maarten C. C. M., van den Berg, Hetty A., Smilde, Tineke J., Vanneste, Ben G. L., Aarts, Maureen J., van den Bergh, Alphonsus C. M., Kerst, J. Martijn, van den Belt-Dusebout, Alexandra W., Lubberts, Sjoukje, Jóźwiak, Katarzina, Horenblas, Simon, van Leeuwen, Flora E., and Schaapveld, Michael

Published
2018
Full Text
View/download PDF

16. Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer

Author

Boekel, Naomi B., Jacobse, Judy N., Schaapveld, Michael, Hooning, Maartje J., Gietema, Jourik A., Duane, Frances K., Taylor, Carolyn W., Darby, Sarah C., Hauptmann, Michael, Seynaeve, Caroline M., Baaijens, Margreet H. A., Sonke, Gabe S., Rutgers, Emiel J. T., Russell, Nicola S., Aleman, Berthe M. P., and van Leeuwen, Flora E.

Published
2018
Full Text
View/download PDF

19. Work and education interruption in long-term Hodgkin lymphoma survivors: an analysis among patients from nine EORTC-LYSA trials

Author

Juul, Sidsel J., primary, Rossetti, Sára, additional, Kicinski, Michal, additional, van der Kaaij, Marleen A. E., additional, Giusti, Francesco, additional, Meijnders, Paul, additional, Aleman, Berthe M. P., additional, Raemaekers, John M. M., additional, Kluin-Nelemans, Hanneke C., additional, Spina, Michele, additional, Fermé, Christophe, additional, Renaud, Loïc, additional, Casasnovas, Olivier, additional, Stamatoullas, Aspasia, additional, André, Marc, additional, Le Bras, Fabien, additional, Plattel, Wouter J., additional, Henry-Amar, Michel, additional, Hutchings, Martin, additional, and Maraldo, Maja V., additional

Published
2023
Full Text
View/download PDF

20. Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma

Author

Vries, S. de, Haaksma, Miriam L., Jozwiak, K., Schaapveld, M., Hodgson, D., Lugtenburg, Pieternella J., Spronsen, D.J. van, Aleman, Berthe M. P., Leeuwen, F.E. van, Vries, S. de, Haaksma, Miriam L., Jozwiak, K., Schaapveld, M., Hodgson, D., Lugtenburg, Pieternella J., Spronsen, D.J. van, Aleman, Berthe M. P., and Leeuwen, F.E. van

Abstract

Item does not contain fulltext

Published
2023

21. Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma

Author

MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, de Vries, Simone, Haaksma, Miriam L, Jóźwiak, Katarzyna, Schaapveld, Michael, Hodgson, David C, Lugtenburg, Pieternella J, Krol, Augustinus D G, Petersen, Eefke J, van Spronsen, Dick Johan, Ahmed, Sameera, Hauptmann, Michael, Aleman, Berthe M P, van Leeuwen, Flora E, MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, de Vries, Simone, Haaksma, Miriam L, Jóźwiak, Katarzyna, Schaapveld, Michael, Hodgson, David C, Lugtenburg, Pieternella J, Krol, Augustinus D G, Petersen, Eefke J, van Spronsen, Dick Johan, Ahmed, Sameera, Hauptmann, Michael, Aleman, Berthe M P, and van Leeuwen, Flora E

Published
2023

24. Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer Among Survivors of Hodgkin Lymphoma

Author

Geurts, Yvonne M., primary, Shakir, Rebecca, additional, Ntentas, Georgios, additional, Roberti, Sander, additional, Aznar, Marianne C., additional, John, Katinka M., additional, Ramroth, Johanna, additional, Janus, Cécile P. M., additional, Krol, Augustinus D. G., additional, Roesink, Judith M., additional, van der Maazen, Richard W. M., additional, Zijlstra, Josée M., additional, Darby, Sarah C., additional, Aleman, Berthe M. P., additional, van Leeuwen, Flora E., additional, Cutter, David J., additional, and Schaapveld, Michael, additional

Published
2023
Full Text
View/download PDF

25. Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials

Author

Maraldo, Maja V, Giusti, Francesco, Vogelius, Ivan R, Lundemann, Michael, van der Kaaij, Marleen A E, Ramadan, Safaa, Meulemans, Bart, Henry-Amar, Michel, Aleman, Berthe M P, Raemaekers, John, Meijnders, Paul, Moser, Elisabeth C, Kluin-Nelemans, Hanneke C, Feugier, Pierre, Casasnovas, Olivier, Fortpied, Catherine, and Specht, Lena

Published
2015
Full Text
View/download PDF

26. Risk of male breast cancer after Hodgkin lymphoma

Author

van Leeuwen, F. E., Nijdam, A., Aleman, B. M. P., de Boer, J. P., Janus, C. P. M., Mutsaers, P. G. N. J., So-Osman, C., Zijlstra, J. M., Meijer, O. W. M., Rademakers, S. E., Krol, A. D. G., Kersten, M. J., Tonino, S. H., Jalink, M., Daniëls, L. A., van Spronsen, D. J., van der Maazen, R. W. M., Loonen, J., Roesink, J. M., Oostvogels, R., de Weijer, R., Buter, D., de Boer, A., Aarsman, K. M., Oudbier, C. W., Nijziel, M. R., van den Berg, M., Verschueren, K., Schippers, M., Boersma, R. S., Issa, D. E., Plattel, W. J., Stedema, F. G., Koene, H. R., Raymakers, E. R. P. M., Schimmel, E., van Hezewijk, M., Bouma, P., Muller, K., Siemes, C., van der Spek, J. M., Ong, F., Jonkman, A., de Jongh, E., Sprangers, S., Kortleve, J. P., Vermeiden, C. M., Ta, B., Vercoulen, L., Paulissen, J., Posthuma, E. F. M., Brouwer, R. E., Soechit, S., van der Wiel, M., Böhmer, L., Bilgin, M. Y., Kuipers, S., Houmes, M., te Boome, L., Gommers, S., de Vries, Simone, Krul, Inge M., Schaapveld, Michael, Janus, Cecile P. M., Rademakers, Saskia E., Roesink, Judith M., Nijziel, Marten R., Bilgin, Yavuz M., Aleman, Berthe M. P., and van Leeuwen, Flora E.

Published
2023
Full Text
View/download PDF

28. Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials

Author

Juul, Sidsel J., primary, Rossetti, Sára, additional, Kicinski, Michal, additional, van der Kaaij, Marleen A. E., additional, Giusti, Francesco, additional, Meijnders, Paul, additional, Aleman, Berthe M. P., additional, Raemaekers, John M. M., additional, Kluin-Nelemans, Hanneke C., additional, Spina, Michele, additional, Fermé, Christophe, additional, Renaud, Loïc, additional, Casasnovas, Olivier, additional, Stamatoullas, Aspasia, additional, André, Marc, additional, Le Bras, Fabien, additional, Plattel, Wouter J., additional, Henry-Amar, Michel, additional, Hutchings, Martin, additional, and Maraldo, Maja V., additional

Published
2022
Full Text
View/download PDF

29. Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials: A study based on the EORTC‐Dutch late effects cohort‐linked data

Author

Juul, Sidsel Jacobsen, primary, Kicinski, Michal, additional, Schaapveld, Michael, additional, Rossetti, Sára, additional, Aleman, Berthe M. P., additional, Liu, Lifang, additional, van Leeuwen, Flora E., additional, Meijnders, Paul, additional, Krol, Augustinus D. G., additional, Janus, Cécile P. M., additional, Hutchings, Martin, additional, and Maraldo, Maja V., additional

Published
2022
Full Text
View/download PDF

30. Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma

Author

Krul, Inge M., primary, Boekel, Naomi B., additional, Kramer, Iris, additional, Janus, Cécile P. M., additional, Krol, Augustinus D. G., additional, Nijziel, Marten R., additional, Zijlstra, Josée M., additional, van der Maazen, Richard W. M., additional, Roesink, Judith M., additional, Jacobse, Judy N., additional, Schaapveld, Michael, additional, Schmidt, Marjanka K., additional, Opstal‐van Winden, Annemieke W. J., additional, Sonke, Gabe S., additional, Russell, Nicola S., additional, Aleman, Berthe M. P., additional, and van Leeuwen, Flora E., additional

Published
2022
Full Text
View/download PDF

31. P073: Increased risk of colorectal cancer following treatment for Hodgkin lymphoma

Author

Geurts, Yvonne M.G., primary, Shakir, Rebecca, additional, Ntentas, Georgios, additional, Roberti, Sander, additional, Aznar, Marianne, additional, John, Katinka, additional, Ramroth, Johanna, additional, Janus, Cécile P.M., additional, Krol, Augustinus, additional, Roesink, Judith, additional, Van Der Maazen, Richard W.M., additional, Zijlstra, Josée. M., additional, Darby, Sarah, additional, Aleman, Berthe M. P., additional, Van Leeuwen, Flora E., additional, Cutter, David, additional, and Schaapveld, Michael, additional

Published
2022
Full Text
View/download PDF

34. T064: Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors

Author

Neppelenbroek, Suzanne I.M., primary, Geurts, Yvonne M.G., additional, Aleman, Berthe M. P., additional, Janus, Cécile P.M., additional, Lugtenburg, Pieternella J., additional, Rademaker, Saskia E., additional, De Weijer, Roel J., additional, Schippers, Maaike G.A., additional, Ta, Bastiaan D.P., additional, Plattel, Wouter J., additional, Zijlstra, Josée. M., additional, Van Der Maazen, Richard W.M., additional, Nijziel, Marten R., additional, Ong, Francisca, additional, Schimmel, Erik C., additional, Posthuma, Eduardus F.M., additional, Kersten, Marie José, additional, Böhmer, Lara H., additional, Muller, Karin, additional, Koene, Harry R., additional, Te Boome, Liane C.J., additional, Bilgin, Yavuz M., additional, De Jongh, Eva, additional, Van Leeuwen, Flora E., additional, and Schaapveld, Michael, additional

Published
2022
Full Text
View/download PDF

35. P080: The BETER-REFLECT Biobank: a REsource For studies on Late Effects of Cancer Treatment

Author

Mieras, Adinda, primary, Nijdam, Annelies, additional, Aleman, Berthe M. P., additional, Daniels, Laurien, additional, De Jongh, Eva, additional, Janus, Cécile P.M., additional, Krol, Stijn, additional, Ta, Bastiaan D.P., additional, Ong, Francisca, additional, Van Spronsen, Dick Johan, additional, Posthuma, Ward, additional, Plattel, Wouter J., additional, Oostvogels, Rimke, additional, Verschueren, Karijn, additional, Zijlstra, Josée. M., additional, and Van Leeuwen, Flora E., additional

Published
2022
Full Text
View/download PDF

36. Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors:A Cross-Sectional Study

Author

Naaktgeboren, Willeke R, Jacobse, Judy N, Steggink, Lars C, Walenkamp, Annemiek M E, van Harten, Wim H, Stuiver, Martijn M, Aaronson, Neil K, Aleman, Berthe M P, van der Meer, Peter, Schaapveld, Michael, Sonke, Gabe S, Gietema, Jourik A, van Leeuwen, Flora E, May, Anne M, Rehabilitation medicine, APH - Quality of Care, APH - Health Behaviors & Chronic Diseases, Hematology, CCA - Cancer Treatment and quality of life, and Epidemiology and Data Science

Subjects
humanities
Abstract

Background: Higher levels of physical activity are associated with a lower risk of cardiovascular disease in the general population. Whether the same holds for women who underwent treatment for breast cancer is unclear.Objectives: The aim of this study was to evaluate the association between physical activity in a typical week in the past 12 months and cardiac dysfunction in breast cancer survivors.Methods: We used data from a cohort of breast cancer survivors who were treated at ages 40 to 50 years (N = 559). The association between physical activity and global longitudinal strain (GLS) and left ventricular ejection fraction (LVEF) was evaluated using both linear and modified Poisson regression analyses adjusted for relevant confounders.Results: In total, 559 breast cancer survivors were included, with median age of 55.5 years and a median time since treatment of 10.2 years. GLS was less favorable in inactive survivors (-17.1%) than in moderately inactive (-18.4%), moderately active (-18.2%), and active survivors (-18.5%), with an adjusted significant difference for active versus inactive survivors (β = -1.31; 95% CI: -2.55 to -0.06)). Moderately active (n = 57/130) and active survivors (n = 87/124) had significantly lower risks of abnormal GLS (defined as >-18%) compared with inactive survivors (n = 17/26) (RR: 0.65 [95% CI: 0.45-0.94] and RR: 0.61 [95% CI: 0.43-0.87], respectively). LVEF, in normal ranges in all activity categories, was not associated with physical activity.Conclusions: In long-term breast cancer survivors, higher physical activity levels were associated with improved GLS but not LVEF, with the relatively largest benefit for doing any activity versus none. This finding suggests that increasing physical activity may contribute to cardiovascular health benefits, especially in inactive survivors.

Published
2022
Full Text
View/download PDF

37. Radiotherapy-Related Dose and Irradiated Volume Effects on Breast Cancer Risk Among Hodgkin Lymphoma Survivors

Author

Roberti, Sander, primary, van Leeuwen, Flora E, additional, Ronckers, Cécile M, additional, Krul, Inge M, additional, de Vathaire, Florent, additional, Veres, Cristina, additional, Diallo, Ibrahima, additional, Janus, Cécile P M, additional, Aleman, Berthe M P, additional, Russell, Nicola S, additional, and Hauptmann, Michael, additional

Published
2022
Full Text
View/download PDF

38. Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors: A Cross-Sectional Study

Author

Naaktgeboren, Willeke R, Groen, Wim G, Jacobse, Judy N, Steggink, Lars C, Walenkamp, Annemiek M E, van Harten, Wim H, Stuiver, Martijn M, Aaronson, Neil K, Aleman, Berthe M P, van der Meer, Peter, Schaapveld, Michael, Sonke, Gabe S, Gietema, Jourik A, van Leeuwen, Flora E, May, Anne M, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Cardiovascular Centre (CVC), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), Master Evidence Based Practice, APH - Health Behaviors & Chronic Diseases, APH - Quality of Care, CCA - Cancer Treatment and Quality of Life, Health Technology & Services Research, Rehabilitation medicine, Hematology, and Epidemiology and Data Science

Subjects
breast cancer, echocardiography, heart failure, lifestyle risk factors
Abstract

Background: Higher levels of physical activity are associated with a lower risk of cardiovascular disease in the general population. Whether the same holds for women who underwent treatment for breast cancer is unclear. Objectives: The aim of this study was to evaluate the association between physical activity in a typical week in the past 12 months and cardiac dysfunction in breast cancer survivors. Methods: We used data from a cohort of breast cancer survivors who were treated at ages 40 to 50 years (N = 559). The association between physical activity and global longitudinal strain (GLS) and left ventricular ejection fraction (LVEF) was evaluated using both linear and modified Poisson regression analyses adjusted for relevant confounders. Results: In total, 559 breast cancer survivors were included, with median age of 55.5 years and a median time since treatment of 10.2 years. GLS was less favorable in inactive survivors (-17.1%) than in moderately inactive (-18.4%), moderately active (-18.2%), and active survivors (-18.5%), with an adjusted significant difference for active versus inactive survivors (β = -1.31; 95% CI: -2.55 to -0.06)). Moderately active (n = 57/130) and active survivors (n = 87/124) had significantly lower risks of abnormal GLS (defined as >-18%) compared with inactive survivors (n = 17/26) (RR: 0.65 [95% CI: 0.45-0.94] and RR: 0.61 [95% CI: 0.43-0.87], respectively). LVEF, in normal ranges in all activity categories, was not associated with physical activity. Conclusions: In long-term breast cancer survivors, higher physical activity levels were associated with improved GLS but not LVEF, with the relatively largest benefit for doing any activity versus none. This finding suggests that increasing physical activity may contribute to cardiovascular health benefits, especially in inactive survivors.

Published
2022

39. Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Juul, Sidsel J, Rossetti, Sára, Kicinski, Michal, van der Kaaij, Marleen A E, Giusti, Francesco, Meijnders, Paul, Aleman, Berthe M P, Raemaekers, John M M, Kluin-Nelemans, Hanneke C, Spina, Michele, Fermé, Christophe, Renaud, Loïc, Casasnovas, Olivier, Stamatoullas, Aspasia, André, Marc, Le Bras, Fabien, Plattel, Wouter J, Henry-Amar, Michel, Hutchings, Martin, Maraldo, Maja V, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Juul, Sidsel J, Rossetti, Sára, Kicinski, Michal, van der Kaaij, Marleen A E, Giusti, Francesco, Meijnders, Paul, Aleman, Berthe M P, Raemaekers, John M M, Kluin-Nelemans, Hanneke C, Spina, Michele, Fermé, Christophe, Renaud, Loïc, Casasnovas, Olivier, Stamatoullas, Aspasia, André, Marc, Le Bras, Fabien, Plattel, Wouter J, Henry-Amar, Michel, Hutchings, Martin, and Maraldo, Maja V

Abstract

Little is known about the employment situation of long-term Hodgkin lymphoma (HL) survivors despite their young age at diagnosis and the favorable prognosis of the disease. In this cross-sectional study, we aim to describe the employment situation in a cohort of long-term HL survivors compared to the general population and investigate the associations with disease characteristics and treatment exposure. HL survivors > 25 years (n = 1961) were matched 1:25 to controls (n = 49,025) from the European Union Labour Force Survey. Individual treatment information was obtained from trial records. Employment and socio-demographic characteristics were collected using the Life Situation Questionnaire. Logistic regression models were used to estimate associations between disease and treatment characteristics with employment status and work-related attitudes. At employment assessment, 69.7% of survivors (95% CI: 67.6-71.7%) were working; of these, 68.9% (95% CI: 66.3-71.3%) worked full-time, a figure comparable to that of controls (p value 0.17). The risk of not working was associated with increasing age at diagnosis, increasing age at survey, female sex, lower educational level, and relapse history. Of those who were at work during treatment, 16.8% (95% CI: 14.5-19.3%) stated their income had subsequently decreased, which was attributed to their HL by 65.4% (95% CI: 57.5-72.8). Among those not at work, 25.1% (95% CI: 20.7-29.8) survivors were disabled compared to only 14.5% (95% CI: 13.8-15.3%) of controls. In this cohort of HL survivors, employment status was comparable to that of the general population. However, increasing age at follow-up, female sex, lower educational level, and relapse history are risk factors for unemployment, a perceived decrease in income, and disability. To further improve follow-up care, special attention should be paid to these vulnerable subgroups.

Published
2022

40. Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma

Author

MS Radiotherapie, Cancer, Krul, Inge M, Boekel, Naomi B, Kramer, Iris, Janus, Cécile P M, Krol, Augustinus D G, Nijziel, Marten R, Zijlstra, Josée M, van der Maazen, Richard W M, Roesink, Judith M, Jacobse, Judy N, Schaapveld, Michael, Schmidt, Marjanka K, Opstal-van Winden, Annemieke W J, Sonke, Gabe S, Russell, Nicola S, Aleman, Berthe M P, van Leeuwen, Flora E, MS Radiotherapie, Cancer, Krul, Inge M, Boekel, Naomi B, Kramer, Iris, Janus, Cécile P M, Krol, Augustinus D G, Nijziel, Marten R, Zijlstra, Josée M, van der Maazen, Richard W M, Roesink, Judith M, Jacobse, Judy N, Schaapveld, Michael, Schmidt, Marjanka K, Opstal-van Winden, Annemieke W J, Sonke, Gabe S, Russell, Nicola S, Aleman, Berthe M P, and van Leeuwen, Flora E

Published
2022

41. Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors: A Cross-Sectional Study

Author

Epi Kanker Team B, Cancer, Externen Med. Onco, Epi Kanker, JC onderzoeksprogramma Cancer, Naaktgeboren, Willeke R, Groen, Wim G, Jacobse, Judy N, Steggink, Lars C, Walenkamp, Annemiek M E, van Harten, Wim H, Stuiver, Martijn M, Aaronson, Neil K, Aleman, Berthe M P, van der Meer, Peter, Schaapveld, Michael, Sonke, Gabe S, Gietema, Jourik A, van Leeuwen, Flora E, May, Anne M, Epi Kanker Team B, Cancer, Externen Med. Onco, Epi Kanker, JC onderzoeksprogramma Cancer, Naaktgeboren, Willeke R, Groen, Wim G, Jacobse, Judy N, Steggink, Lars C, Walenkamp, Annemiek M E, van Harten, Wim H, Stuiver, Martijn M, Aaronson, Neil K, Aleman, Berthe M P, van der Meer, Peter, Schaapveld, Michael, Sonke, Gabe S, Gietema, Jourik A, van Leeuwen, Flora E, and May, Anne M

Published
2022

42. Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials: A study based on the EORTC‐Dutch late effects cohort‐linked data.

Author

Juul, Sidsel Jacobsen, Kicinski, Michal, Schaapveld, Michael, Rossetti, Sára, Aleman, Berthe M. P., Liu, Lifang, van Leeuwen, Flora E., Meijnders, Paul, Krol, Augustinus D. G., Janus, Cécile P. M., Hutchings, Martin, and Maraldo, Maja V.

Subjects
HODGKIN'S disease, CLINICAL trials, OVERALL survival, UNITS of time
Abstract

Studies have shown higher survival rates for patients with Hodgkin lymphoma (HL) treated within clinical trials compared to patients treated outside clinical trials. However, endpoints are often limited to overall survival (OS). In this retrospective cohort study, we investigated the effect of trial participation on OS, the incidence of relapse, second cancer, and cardiovascular disease (CVD). The study population consisted of patients with HL, aged between 14 and 51 years at diagnosis, who started their treatment between 1962 and 2002 at three Dutch cancer centres. Patients were either included in the EORTC Lymphoma Group trials (H1–H9) or treated according to standard guidelines at the time. After adjusting for differences in baseline characteristics, trial participation was associated with longer OS (median OS: 29.4 years [95%CI: 27.0–31.6] for treatment inside trials versus 27.4 years [95%CI: 26.0–28.5] for treatment outside trials, p =.046), a lower incidence of relapse (HR = 0.79, 95%CI: 0.63–0.98, p =.036) and a higher incidence of CVD (HR = 1.49, 95%CI: 1.23–1.79, p <.001). The trial effect for CVD was present only for patients treated before 1983. No evidence of differences in the incidence of second cancer was found. Consequently, essential results from clinical trials should be implemented into standard practice without undue delay. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy.

Author

Ykema, Berbel L. M., Gini, Andrea, Rigter, Lisanne S., Spaander, Manon C. W., Moons, Leon M. G., Bisseling, Tanya M., de Boer, Jan Paul, Verbeek, Wieke H. M., Lugtenburg, Pieternella J., Janus, Cecile P. M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W. M., Aleman, Berthe M. P., Meijer, Gerrit A., van Leeuwen, Flora E., Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E., and Lansdorp-Vogelaar, Iris

Abstract

Background: Hodgkin lymphoma survivors treated with infradiaphragmatic radiotherapy (IRT) and/or procarbazine have an increased risk of developing colorectal cancer. We investigated the cost-effectiveness of colorectal cancer surveillance in Dutch Hodgkin lymphoma survivors to determine the optimal surveillance strategy for different Hodgkin lymphoma subgroups. Methods: The Microsimulation Screening Analysis-Colon model was adjusted to reflect colorectal cancer and other-cause mortality risk in Hodgkin lymphoma survivors. Ninety colorectal cancer surveillance strategies were evaluated varying in starting and stopping age, interval, and modality [colonoscopy, fecal immunochemical test (FIT, OC-Sensor; cutoffs: 10/20/47 µg Hb/g feces), and multi-target stool DNA test (Cologuard)]. Analyses were also stratified per primary treatment (IRT and procarbazine or procarbazine without IRT). Colorectal cancer deaths averted (compared with no surveillance) and incremental cost-effectiveness ratios (ICER) were primary outcomes. The optimal surveillance strategy was identified assuming a willingness-to-pay threshold of €20,000 per life-years gained (LYG). Results: Overall, the optimal surveillance strategy was annual FIT (47 µg) from age 45 to 70 years, which might avert 70% of colorectal cancer deaths in Hodgkin lymphoma survivors (compared with no surveillance; ICER:€18,000/LYG). The optimal surveillance strategy in Hodgkin lymphoma survivors treated with procarbazine without IRT was biennial FIT (47 µg) from age 45 to 70 years (colorectal cancer mortality averted 56%; ICER:€15,000/LYG), and when treated with IRT and procarbazine, annual FIT (47 µg) surveillance from age 40 to 70 was most cost-effective (colorectal cancer mortality averted 75%; ICER:€13,000/LYG). Conclusions: Colorectal cancer surveillance in Hodgkin lymphoma survivors is cost-effective and should commence earlier than screening occurs in population screening programs. For all subgroups, FIT surveillance was the most cost-effective strategy. Impact: Colorectal cancer surveillance should be implemented in Hodgkin lymphoma survivors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin’s lymphoma survivors

Author

Ykema, Berbel L. M., primary, Rigter, Lisanne S., additional, Spaander, Manon C. W., additional, Moons, Leon M. G., additional, Bisseling, Tanya M., additional, Aleman, Berthe M. P., additional, Dekker, Evelien, additional, Verbeek, Wieke H. M., additional, Kuipers, Ernst J., additional, Boer, Jan Paul, additional, Lugtenburg, Pieternella J., additional, Janus, Cecile P. M., additional, Petersen, Eefke J., additional, Roesink, Judith M., additional, Maazen, Richard W. M., additional, Meijer, Gerrit A., additional, Schaapveld, Michael, additional, Leeuwen, Flora E., additional, Carvalho, Beatriz, additional, Snaebjornsson, Petur, additional, and Leerdam, Monique E., additional

Published
2021
Full Text
View/download PDF

50. Long-term cause-specific mortality in hodgkin lymphoma patients

Author

MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, MS Radiotherapie, de Vries, Simone, Schaapveld, Michael, Janus, Cécile P M, Daniëls, Laurien A, Petersen, Eefke J, van der Maazen, Richard W M, Zijlstra, Josée M, Beijert, Max, Nijziel, Marten R, Verschueren, Karijn M S, Kremer, Leontien C M, van Eggermond, Anna M, Lugtenburg, Pieternella J, Krol, Augustinus D G, Roesink, Judith M, Plattel, Wouter J, van Spronsen, Dick Johan, van Imhoff, Gustaaf W, de Boer, Jan Paul, Aleman, Berthe M P, van Leeuwen, Flora E, MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, MS Radiotherapie, de Vries, Simone, Schaapveld, Michael, Janus, Cécile P M, Daniëls, Laurien A, Petersen, Eefke J, van der Maazen, Richard W M, Zijlstra, Josée M, Beijert, Max, Nijziel, Marten R, Verschueren, Karijn M S, Kremer, Leontien C M, van Eggermond, Anna M, Lugtenburg, Pieternella J, Krol, Augustinus D G, Roesink, Judith M, Plattel, Wouter J, van Spronsen, Dick Johan, van Imhoff, Gustaaf W, de Boer, Jan Paul, Aleman, Berthe M P, and van Leeuwen, Flora E

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results